tldrdailynews.com logo
Tag

Abbvie

All articles tagged with #abbvie

AbbVie to Acquire Apogee for $10.9B to Snag Eczema Drug Candidate
business19 days ago

AbbVie to Acquire Apogee for $10.9B to Snag Eczema Drug Candidate

AbbVie agreed to acquire Apogee Therapeutics for $10.9 billion in cash, gaining control of zumilokibart, a late-stage anti-IL-13 eczema antibody that could compete with Lilly’s Ebglyss and Regeneron/Sanofi’s Dupixent. The deal complements AbbVie’s immunology portfolio (Skyrizi, Rinvoq) and may offer less frequent dosing (every 3–6 months) based on Phase 2 data. Apogee previously secured up to $1.3 billion from Blackstone Life Sciences, and the transaction values the stock at $135.11 per share. Key milestones include one-year Phase 2 data anticipated in early 2027 and Phase 3 data in 2028."

via Fierce Biotech|
#abbvie#acquisition#apogee-therapeutics
business19 days ago

AbbVie to Buy Apogee Therapeutics, Expanding Immunology Pipeline

AbbVie will acquire Apogee Therapeutics for $135.11 per share in cash, valuing Apogee at about $10.9 billion, to broaden AbbVie’s immunology and respiratory portfolio. Apogee’s lead asset zumilokibart (APG777) is an IL-13–targeting monoclonal antibody for atopic dermatitis, with APG273 (a combo with anti-TSLP antibody APG333) in asthma, plus additional antibody programs. The transaction is expected to close in Q3 2026, subject to regulatory and shareholder approvals, and is anticipated to be accretive to AbbVie’s adjusted EPS beginning in 2032. An AbbVie investor conference call is planned for June 22, 2026."

via AbbVie News Center|
#abbvie#apg273#apogee-therapeutics
AbbVie inches toward $11 billion bid for Apogee Therapeutics to strengthen immunology pipeline
business21 days ago

AbbVie inches toward $11 billion bid for Apogee Therapeutics to strengthen immunology pipeline

AbbVie is nearing an $11 billion cash deal to acquire Apogee Therapeutics, in what would be its biggest bolt-on in years, paying about $10.9 billion — roughly a 60% premium — for Apogee and its lead inflammatory-disease drug zumilokibart, to bolster AbbVie’s immunology portfolio as Humira faces biosimilar competition.

via Financial Times|
#abbvie#apogee-therapeutics#biotech
AbbVie Bets on Durham: $1.4B Manufacturing Campus to Create 734 Jobs
business2 months ago

AbbVie Bets on Durham: $1.4B Manufacturing Campus to Create 734 Jobs

AbbVie announced a $1.4 billion investment to build a 185-acre pharmaceutical manufacturing campus in Durham, North Carolina, near Research Triangle Park, integrating advanced, AI-enabled manufacturing to support its immunology, neuroscience and oncology medicines. Construction starts in 2026 and is expected to finish by the end of 2028, creating about 734 jobs in manufacturing and laboratory roles, while generating more than 2,000 construction jobs during development. The project represents AbbVie’s largest U.S. capital investment to date and its first major manufacturing footprint in North Carolina, supported by the region’s skilled workforce.

via AbbVie News Center|
#abbvie#business#durham
AbbVie Bets $380 Million on North Chicago API Manufacturing Expansion
business4 months ago

AbbVie Bets $380 Million on North Chicago API Manufacturing Expansion

AbbVie announced a $380 million plan to build two new active pharmaceutical ingredient facilities at its North Chicago campus, with construction starting in spring 2026 and full operation expected by 2029. The AI-enabled manufacturing hubs will support next-generation neuroscience and obesity medicines and are part of AbbVie's broader $100 billion U.S. R&D and capital investments commitment, including plans to hire about 300 local workers.

via AbbVie News Center|
#abbvie#ai#api-manufacturing
healthcare5 months ago

AbbVie, U.S. Government Strike Deal to Expand Access and Invest in Domestic Pharma

AbbVie and the Trump administration announced a three-year agreement to boost U.S. access and affordability: AbbVie will offer low Medicaid prices, expand direct-to-patient access via the TrumpRx program for medicines including ALPHAGAN, COMBIGAN, HUMIRA and SYNTHROID, and commit $100 billion in U.S.-based R&D and manufacturing investments over the next decade, in exchange for tariff relief and exemption from future price mandates; the deal aims to address all four of the President's drug pricing priorities, with terms kept confidential.

via AbbVie News Center|
#abbvie#drug-pricing#healthcare
AbbVie Acquires Gilgamesh's Psychedelic Depression Therapy in $1.2B Deal
business10 months ago

AbbVie Acquires Gilgamesh's Psychedelic Depression Therapy in $1.2B Deal

AbbVie is acquiring Gilgamesh Pharmaceuticals' investigational drug bretisilocin, a promising psychedelic therapy in Phase 2 trials for major depressive disorder, aiming to expand its psychiatric treatment portfolio. The drug has shown significant antidepressant effects with a shorter psychoactive duration, and the deal includes up to $1.2 billion in potential payments. This move underscores AbbVie's commitment to innovative mental health treatments.

via AbbVie News Center|
#abbvie#bretisilocin#business